(Total Views: 71)
Posted On: 09/22/2025 4:30:29 PM
Post# of 61
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) CEO Featured on IBN’s BioMedWire Podcast
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, is featured in the latest episode of IBN’s BioMedWire Podcast. Chairman and CEO Dr. Vuong Trieu discussed the company’s mission to treat cancer and rare diseases, emphasizing Oncotelic’s expertise in tumor microenvironments, regulatory pathways, and intellectual property strategies. He noted that investors should watch for multiple clinical and regulatory milestones over the next 12 months, including IND approvals, expanded indications, and partnership announcements.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, is featured in the latest episode of IBN’s BioMedWire Podcast. Chairman and CEO Dr. Vuong Trieu discussed the company’s mission to treat cancer and rare diseases, emphasizing Oncotelic’s expertise in tumor microenvironments, regulatory pathways, and intellectual property strategies. He noted that investors should watch for multiple clinical and regulatory milestones over the next 12 months, including IND approvals, expanded indications, and partnership announcements.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
